Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC boosted its position in Replimune Group, Inc. (NASDAQ:REPLGet Rating) by 119.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,302 shares of the company’s stock after purchasing an additional 20,335 shares during the period. Cubist Systematic Strategies LLC owned about 0.07% of Replimune Group worth $644,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Swiss National Bank raised its stake in shares of Replimune Group by 8.2% during the 1st quarter. Swiss National Bank now owns 49,900 shares of the company’s stock worth $847,000 after buying an additional 3,800 shares in the last quarter. MetLife Investment Management LLC raised its position in Replimune Group by 54.2% in the first quarter. MetLife Investment Management LLC now owns 15,209 shares of the company’s stock worth $258,000 after acquiring an additional 5,344 shares in the last quarter. Rhumbline Advisers raised its position in Replimune Group by 5.2% in the first quarter. Rhumbline Advisers now owns 32,643 shares of the company’s stock worth $554,000 after acquiring an additional 1,616 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Replimune Group by 48.1% in the first quarter. Dimensional Fund Advisors LP now owns 344,397 shares of the company’s stock valued at $5,848,000 after acquiring an additional 111,920 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Replimune Group by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 1,625,758 shares of the company’s stock worth $27,606,000 after purchasing an additional 81,845 shares in the last quarter. Hedge funds and other institutional investors own 87.83% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. SVB Leerink increased their price target on shares of Replimune Group from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Wednesday, December 7th. HC Wainwright lifted their price target on shares of Replimune Group from $48.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, February 10th. Piper Sandler upped their price target on Replimune Group from $43.00 to $58.00 in a report on Wednesday, December 14th. BMO Capital Markets raised their price objective on Replimune Group from $40.00 to $70.00 and gave the company an “outperform” rating in a research note on Monday, December 12th. Finally, EF Hutton Acquisition Co. I initiated coverage on Replimune Group in a research report on Thursday, January 5th. They set a “buy” rating and a $60.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $51.86.

Replimune Group Stock Down 6.1 %

REPL stock opened at $18.65 on Friday. The company has a 50 day moving average price of $25.31 and a two-hundred day moving average price of $21.83. The company has a debt-to-equity ratio of 0.09, a quick ratio of 23.58 and a current ratio of 23.58. The stock has a market capitalization of $1.06 billion, a P/E ratio of -6.52 and a beta of 1.69. Replimune Group, Inc. has a one year low of $13.05 and a one year high of $29.52.

Replimune Group Company Profile

(Get Rating)

Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.

Featured Articles

Institutional Ownership by Quarter for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.